|
US359439A
(en)
|
|
1887-03-15 |
|
Thomas f |
|
US378130A
(en)
|
|
1888-02-21 |
|
Apparatus foe inserting and fixing the bristles of beushes |
|
US2774763A
(en)
|
|
1956-12-18 |
|
Preparation of amides of lysergic age |
|
US860913A
(en)
|
1906-09-13 |
1907-07-23 |
Max Haeberlein |
Oil-brake for speed-governors.
|
|
US2997470A
(en)
|
1956-03-05 |
1961-08-22 |
Lilly Co Eli |
Lysergic acid amides
|
|
GB912715A
(en)
|
1958-02-21 |
1962-12-12 |
Sandoz Ltd |
4-hydroxytryptamines
|
|
US3078214A
(en)
|
1958-09-12 |
1963-02-19 |
Sandoz Ag |
Treatment of mental disturbances with esters of indoles
|
|
GB981192A
(en)
|
1960-03-30 |
1965-01-20 |
Westminster Bank Ltd |
Improvements in or relating to 4 hydroxytryptamine esters
|
|
US3224945A
(en)
|
1963-05-06 |
1965-12-21 |
College Of Pharmacy |
Process for the production of ergot alkaloids
|
|
GB1164828A
(en)
|
1965-10-23 |
1969-09-24 |
Robins Co Inc A H |
3-(2-Substituted Ethyl)Indoles and their Manufacture and Use
|
|
US3781300A
(en)
*
|
1969-06-09 |
1973-12-25 |
American Home Prod |
Method of producing 2-halo-3-substituted indoles
|
|
US3594391A
(en)
|
1969-06-09 |
1971-07-20 |
American Home Prod |
2-halo-3-substituted indoles
|
|
BE792515A
(fr)
|
1971-12-10 |
1973-06-08 |
Sandoz Sa |
Nouveaux derives de l'acide lysergique, leur preparation et leur application comme medicaments
|
|
CH578565A5
(en)
|
1972-12-07 |
1976-08-13 |
Sandoz Ag |
N-(2-amino-5-pyridyl) lysergic acid amides - with saluretic and serotonin antagonist activity
|
|
HU172649B
(hu)
|
1975-04-24 |
1978-11-28 |
Gyogyszerkutato Intezet |
Sposob poluchenija novykh biologicheski aktivnykh lizergamidov
|
|
DE2656344A1
(de)
|
1975-12-23 |
1977-07-07 |
Sandoz Ag |
Ergolinderivate, ihre verwendung und herstellung
|
|
IT1064473B
(it)
|
1976-11-24 |
1985-02-18 |
Simes |
Sulfamoil derivati dell'8-beta-amminometilergolina
|
|
DE2802023A1
(de)
|
1977-01-28 |
1978-08-03 |
Sandoz Ag |
Neue ergotderivate, ihre herstellung und verwendung
|
|
GB1584464A
(en)
|
1977-04-19 |
1981-02-11 |
Farmaceutici Italia |
Ergot alkaloids
|
|
AU526764B2
(en)
|
1978-09-08 |
1983-01-27 |
Farmitalia Carlo Erba S.P.A. |
Ergoline derivatives
|
|
ZA795239B
(en)
|
1978-10-12 |
1980-11-26 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
EP0026899A1
(de)
|
1979-10-09 |
1981-04-15 |
Sandoz Ag |
Peptidergotalkaloide, Verfahren zu deren Herstellung, diese enthaltende pharmakologische Zusammensetzungen und ihre Anwendung bei der therapeutischen Behandlung
|
|
GB8318790D0
(en)
|
1983-07-12 |
1983-08-10 |
Erba Farmitalia |
Anorexigenic ergot derivatives
|
|
US5340838A
(en)
|
1990-05-04 |
1994-08-23 |
Eli Lilly And Company |
Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
|
|
CA2102303A1
(en)
|
1991-06-19 |
1992-12-20 |
Roy Allen Johnson |
Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents
|
|
JP3361836B2
(ja)
|
1991-07-04 |
2003-01-07 |
三共株式会社 |
アミノ酸誘導体
|
|
GB9226532D0
(en)
|
1992-12-21 |
1993-02-17 |
Smithkline Beecham Plc |
Compounds
|
|
WO1995006638A1
(en)
|
1993-09-01 |
1995-03-09 |
Allelix Biopharmaceuticals Inc. |
Tryptamine analogs with 5-ht1d selectivity
|
|
GB9402029D0
(en)
|
1994-02-03 |
1994-03-30 |
Smithkline Beecham Plc |
Novel formulation
|
|
JPH09510216A
(ja)
|
1994-03-11 |
1997-10-14 |
イーライ・リリー・アンド・カンパニー |
5−ht▲下2b▼受容体に関連する病態を治療するための方法
|
|
US6025374A
(en)
|
1994-12-06 |
2000-02-15 |
Merck Sharp & Dohme, Ltd. |
Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
|
|
WO1997043281A1
(en)
|
1996-05-16 |
1997-11-20 |
Allelix Biopharmaceuticals Inc. |
Thiophene- and furan-tryptamine derivatives
|
|
EP0821957A3
(en)
*
|
1996-08-01 |
1998-04-22 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
|
|
US6500456B1
(en)
|
1997-10-03 |
2002-12-31 |
Warner-Lambert Company |
Compressed nitroglycerin tablet and its method of manufacture
|
|
DE19803376C1
(de)
|
1998-01-29 |
1999-10-14 |
Markus Storz |
Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
|
|
US6436950B1
(en)
|
1998-08-14 |
2002-08-20 |
Nastech Pharmaceutical Company, Inc. |
Nasal delivery of apomorphine
|
|
NZ510988A
(en)
|
1998-10-07 |
2005-01-28 |
Ortho Mcneil Pharm Inc |
N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
|
|
US6376531B1
(en)
|
1998-11-13 |
2002-04-23 |
Rupert Charles Bell |
Method of treatment using deuterium compounds
|
|
US6403808B1
(en)
|
1999-12-10 |
2002-06-11 |
Virginia Commonwealth University |
Selective 5-HT6 receptor ligands
|
|
US6488648B1
(en)
|
1999-01-14 |
2002-12-03 |
Teijin Limited |
Device for feeding a powder in a predetermined amount and method thereof
|
|
NZ514442A
(en)
|
1999-03-03 |
2003-08-29 |
Optinose As |
Nasal delivery device
|
|
GB0114272D0
(en)
|
2001-06-12 |
2001-08-01 |
Optinose As |
Nasal delivery device
|
|
GB0121568D0
(en)
|
2001-09-06 |
2001-10-24 |
Optinose As |
Nasal delivery device
|
|
HUP0202143A3
(en)
|
1999-07-28 |
2003-12-29 |
Ortho Mcneil Pharm Inc |
Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
|
|
WO2001015677A2
(en)
|
1999-08-31 |
2001-03-08 |
Alcon Laboratories, Inc. |
Use of 5-ht1b/1d agonists to treat otic pain
|
|
DE10007948A1
(de)
|
2000-02-22 |
2001-09-06 |
Wella Ag |
Mittel zur Färbung von Fasern
|
|
US20020052370A1
(en)
|
2000-07-06 |
2002-05-02 |
Barber Christopher Gordon |
Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
|
|
ES2172415B2
(es)
|
2000-07-28 |
2003-11-16 |
Univ Madrid Complutense |
Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
|
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
|
GB0019715D0
(en)
|
2000-08-10 |
2000-09-27 |
Pa Consulting Services |
Device for delivering physiologically active agent in powdered form
|
|
WO2002038142A2
(en)
|
2000-11-08 |
2002-05-16 |
Massachusetts Institute Of Technology |
Serotonergic compositions and methods for treatment of mild cognitive impairment
|
|
KR100523257B1
(ko)
|
2000-12-29 |
2005-10-24 |
삼성전자주식회사 |
포지티브형 감광성 폴리이미드 전구체 및 이를 포함하는조성물
|
|
ZA200306564B
(en)
|
2001-02-26 |
2004-10-15 |
Optinose As |
Nasal devices.
|
|
ES2566056T3
(es)
|
2001-03-29 |
2016-04-08 |
Eli Lilly And Company |
N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
|
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
|
ITRM20010356A1
(it)
|
2001-06-21 |
2002-12-23 |
Sigma Tau Ind Farmaceuti |
"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
|
|
US20050245594A1
(en)
|
2001-06-29 |
2005-11-03 |
Sutter Diane E |
Dermal delivery of anti-pain agents and methods useful thereof
|
|
GB0117827D0
(en)
|
2001-07-21 |
2001-09-12 |
Igt Uk Ltd |
Entertainment machines
|
|
AU2002340083A1
(en)
|
2001-09-28 |
2003-04-07 |
Kurve Technology, Inc |
Nasal nebulizer
|
|
ITMI20012174A1
(it)
|
2001-10-18 |
2003-04-18 |
Univ Parma |
Polvere per somministrazione nasale di farmaci
|
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
GB0207422D0
(en)
|
2002-03-28 |
2002-05-08 |
Optinose As |
Nasal devices
|
|
GB0207817D0
(en)
|
2002-04-04 |
2002-05-15 |
Optinose As |
Nasal devices
|
|
GB0209494D0
(en)
|
2002-04-25 |
2002-06-05 |
Optinose As |
Nasal devices
|
|
ES2297216T3
(es)
|
2002-06-21 |
2008-05-01 |
Suven Life Sciences Limited |
Indoles tetraciclicos arilsulfonil que tienen afinidad con el receptor de la serotonina.
|
|
WO2004030075A1
(ja)
|
2002-09-26 |
2004-04-08 |
Renesas Technology Corp. |
半導体装置の製造方法
|
|
CN1685732B
(zh)
|
2002-11-01 |
2010-10-13 |
松下电器产业株式会社 |
画像编码方法及装置、画像解码方法及装置
|
|
US20040127409A1
(en)
|
2002-11-07 |
2004-07-01 |
Milkhaus Laboratory, Inc. |
Method of treatment of psychological conditions by administration of nerve growth factor
|
|
WO2004085392A1
(en)
|
2003-03-25 |
2004-10-07 |
Faust Pharmaceuticals |
Melatonin derivatives and their use for treating neurological dysfunctions
|
|
US20040214832A1
(en)
|
2003-04-10 |
2004-10-28 |
Cuiman Cai |
Piperazine derivative renin inhibitors
|
|
CA2526478A1
(en)
|
2003-05-21 |
2004-12-02 |
Alexza Pharmaceuticals, Inc. |
Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
|
|
US20050152858A1
(en)
|
2003-07-11 |
2005-07-14 |
Isp Investments Inc. |
Solubilizing agents for active or functional organic compounds
|
|
JP2005102086A
(ja)
|
2003-09-26 |
2005-04-14 |
Renesas Technology Corp |
半導体装置およびレベル変換回路
|
|
JP2005122773A
(ja)
|
2003-10-14 |
2005-05-12 |
Matsushita Electric Ind Co Ltd |
光ディスク装置および信号処理装置と光ディスク装置の再生制御方法
|
|
AU2005244770A1
(en)
|
2004-04-26 |
2005-12-01 |
Vanderbilt University |
Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
|
|
DE102004036034B3
(de)
|
2004-07-24 |
2005-11-24 |
Robert Bosch Gmbh |
Verfahren zur Steuerung einer Brennkraftmaschine
|
|
WO2006099416A1
(en)
|
2005-03-11 |
2006-09-21 |
Nitromed, Inc. |
2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
|
KR100860544B1
(ko)
|
2005-03-14 |
2008-09-26 |
윤석태 |
스플리트 롤러 베어링 케이지의 자기 체결장치
|
|
WO2006105615A1
(en)
*
|
2005-04-08 |
2006-10-12 |
Ozpharma Pty Ltd |
Buccal delivery system
|
|
JP2008547157A
(ja)
|
2005-06-01 |
2008-12-25 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
再充電できるリチウムイオン電池用のカソード
|
|
EP1962837A4
(en)
|
2005-12-20 |
2011-12-14 |
Teikoku Pharma Usa Inc |
METHODS OF PERCUTANEOUS DELIVERY OF INDOLIC SEROTONIN RECEPTOR AGONIST AND PERCUTANEOUS COMPOSITIONS FOR USE THEREIN
|
|
US7429575B2
(en)
|
2006-01-10 |
2008-09-30 |
Yu Ruey J |
N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
|
|
CA2642685A1
(en)
|
2006-02-17 |
2007-08-30 |
Gilead Colorado, Inc. |
Antihypertensive therapy
|
|
HRP20120479T1
(hr)
|
2006-06-28 |
2012-07-31 |
Chelsea@Therapeutics@Inc |
Farmaceutski sastavi sa droksidopom
|
|
CN2920112Y
(zh)
|
2006-07-03 |
2007-07-11 |
于乔治 |
带有热水杀菌系统的桶装水饮水机
|
|
DE502006008441D1
(de)
|
2006-08-01 |
2011-01-13 |
Stobi Gmbh & Co Kg |
Ventilballon für Inhalatoren
|
|
ATE453416T1
(de)
|
2006-08-23 |
2010-01-15 |
Blue Medical Devices B V |
Medizinischer stent mit einer kombination aus melatonin und paclitaxel
|
|
US7482273B1
(en)
|
2006-09-11 |
2009-01-27 |
United States Of America As Represented By The Secretary Of The Air Force |
Transmissive dynamic plasma steering method for radiant electromagnetic energy
|
|
EP2420235A1
(en)
|
2006-10-27 |
2012-02-22 |
Medivation Neurology, Inc. |
Methods and combination therapies for treating alzheimer's disease
|
|
US20080293695A1
(en)
|
2007-05-22 |
2008-11-27 |
David William Bristol |
Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
|
|
US20080248511A1
(en)
|
2007-03-26 |
2008-10-09 |
Promega Corporation |
Methods to quench light from optical reactions
|
|
CA2686994A1
(en)
|
2007-05-11 |
2008-11-20 |
Mpex Pharmaceuticals, Inc. |
Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
EP2209380A4
(en)
|
2007-10-09 |
2011-09-14 |
Mark T Hamann |
METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
|
|
EP2083008A1
(en)
|
2007-12-07 |
2009-07-29 |
Axxonis Pharma AG |
Ergoline derivatives as selective radical scavengers for neurons
|
|
EP2240022B1
(en)
|
2008-01-09 |
2016-12-28 |
Charleston Laboratories, Inc. |
Bilayered tablets comprising oxycodone and promethazine
|
|
JP5620907B2
(ja)
*
|
2008-06-19 |
2014-11-05 |
エルテーエスローマン テラピー−ジステーメ アーゲー |
カチオン性活性剤の経皮送達のための組成物
|
|
BRPI0919920A2
(pt)
|
2008-10-22 |
2016-02-16 |
Acucela Inc |
compostos para tratamento de doenças e desordens oftálmicas
|
|
US9433793B2
(en)
|
2008-11-03 |
2016-09-06 |
Pacesetter, Inc. |
System and method for accurately detecting cardiac events using multi-threshold processing
|
|
WO2010054202A2
(en)
|
2008-11-06 |
2010-05-14 |
Leon Rosenberg |
Package of pills useful for titration and method of titrating a patient
|
|
AU2010251930A1
(en)
|
2009-05-27 |
2011-11-24 |
Universite Libre De Bruxelles |
3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
|
|
WO2010151258A1
(en)
|
2009-06-24 |
2010-12-29 |
The Board Of Regents Of The University Of Oklahoma |
Methods of treating psychological conditions
|
|
US8912220B2
(en)
|
2009-08-10 |
2014-12-16 |
Galenea Pharmaceuticals |
Compounds and methods of use thereof
|
|
WO2011041870A1
(en)
|
2009-10-07 |
2011-04-14 |
Nitrogenix Inc. |
Non-steroidal anti-inflammatory drugs coadministered with nitric oxide amino acid ester compounds as prophylaxis in hypertensive patients
|
|
US20120108510A1
(en)
|
2010-05-20 |
2012-05-03 |
Emory University |
Methods of improving behavioral therapies
|
|
EP2418196A1
(en)
|
2010-07-29 |
2012-02-15 |
IMTM GmbH |
Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
|
|
CN103249407B
(zh)
|
2010-10-07 |
2017-05-17 |
鹰制药私人有限公司 |
用于治疗抑郁症和其他非感染性疾病的联合疗法
|
|
US20140221499A1
(en)
|
2011-06-16 |
2014-08-07 |
President And Fellows Of Harvard College |
Novel rodent control agents and uses thereof
|
|
US9073851B2
(en)
|
2011-10-28 |
2015-07-07 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating cancer
|
|
WO2013142770A1
(en)
|
2012-03-23 |
2013-09-26 |
Codexis, Inc. |
Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
|
|
EP2830599B1
(en)
|
2012-03-29 |
2018-08-15 |
Therabiome, Llc |
Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
|
|
CA2876321A1
(en)
|
2012-06-22 |
2013-12-27 |
Map Pharmaceuticals, Inc. |
Novel cabergoline derivatives
|
|
JP2015521988A
(ja)
*
|
2012-07-06 |
2015-08-03 |
イガレット・リミテッド |
制御放出用乱用防止性医薬組成物
|
|
CN102816103B
(zh)
|
2012-08-20 |
2014-05-07 |
冉瑞琼 |
硫化天冬氨酸修饰的退黑素衍生物及其应用
|
|
US9580400B2
(en)
|
2013-02-26 |
2017-02-28 |
Northeastern University |
Cannabinergic nitrate esters and related analogs
|
|
EP2796139A1
(en)
|
2013-04-26 |
2014-10-29 |
AOP Orphan Pharmaceuticals AG |
Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
|
|
FR3007992B1
(fr)
|
2013-07-05 |
2018-01-26 |
Aptar France Sas |
Dispositif de distribution de produit fluide ou pulverulent.
|
|
US9549942B2
(en)
|
2013-07-15 |
2017-01-24 |
Research & Business Foundation Sungkyunkwan University |
Composition for preventing or treating degenerative brain diseases including compound downregulating expression of BACE1 proteins
|
|
TWI659017B
(zh)
|
2013-11-24 |
2019-05-11 |
臺北醫學大學 |
吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途
|
|
JP6510539B2
(ja)
|
2014-01-09 |
2019-05-08 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ, ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デヴィッド グラッドストーン |
置換ベンゾオキサジン及び関連化合物
|
|
EP3110419A4
(en)
|
2014-02-25 |
2017-07-26 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of complement mediated disorders
|
|
CN103816150A
(zh)
|
2014-03-14 |
2014-05-28 |
兰州理工大学 |
山蚂蝗生物碱单体成分的用途
|
|
GB201409516D0
(en)
|
2014-05-29 |
2014-07-16 |
Randox Lab Ltd |
Immunoassay for compounds of the NBOMe family
|
|
JP6856532B2
(ja)
|
2015-01-20 |
2021-04-07 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
エルゴリン化合物およびその使用
|
|
EP3268086A4
(en)
|
2015-03-10 |
2018-11-07 |
Eleusis Benefit Corporation, PBC |
Lsd for the treatment of alzheimer's disease
|
|
US20180147142A1
(en)
|
2015-05-19 |
2018-05-31 |
Joseph Robert Knight |
Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
|
|
US20220079881A1
(en)
|
2016-03-03 |
2022-03-17 |
Ctt Pharma Inc. |
Orally Administrable Composition
|
|
KR20220071293A
(ko)
|
2016-04-01 |
2022-05-31 |
리커리엄 아이피 홀딩스, 엘엘씨 |
에스트로겐 수용체 조절제
|
|
CN206543131U
(zh)
|
2016-07-08 |
2017-10-10 |
深圳西诺咖啡机制造有限公司 |
一种可酿造多种咖啡胶囊的酿造装置
|
|
US20210069170A1
(en)
|
2016-07-23 |
2021-03-11 |
Paul Edward Stamets |
Tryptamine compositions for enhancing neurite outgrowth
|
|
EP3519816A4
(en)
|
2016-09-29 |
2020-05-06 |
The Regents of the University of California |
CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
|
|
WO2018081456A1
(en)
*
|
2016-10-26 |
2018-05-03 |
University Of Florida Research Foundation, Incorporated |
Highly active self-sufficient nitration biocatalysts
|
|
WO2018094005A1
(en)
|
2016-11-16 |
2018-05-24 |
The General Hospital Corporation |
Myeloperoxidase imaging agents
|
|
WO2018094106A2
(en)
|
2016-11-16 |
2018-05-24 |
University Of South Florida |
ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
|
|
WO2018106907A1
(en)
|
2016-12-08 |
2018-06-14 |
Novatarg, Inc. |
Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
|
|
US11974984B2
(en)
|
2017-02-09 |
2024-05-07 |
Caamtech, Inc. |
Compositions and methods comprising a combination of serotonergic drugs
|
|
KR101934048B1
(ko)
|
2017-03-09 |
2019-03-26 |
고려대학교 산학협력단 |
플라빈-의존형 할로게나아제 및 이를 이용한 할로겐화 인돌 화합물의 제조방법
|
|
US20200147038A1
(en)
|
2017-04-20 |
2020-05-14 |
Eleusis Benefit Corporation, Pbc |
Assessing and treating psychedelic-responsive subjects
|
|
EP3655406A1
(en)
|
2017-07-18 |
2020-05-27 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
JP7403050B2
(ja)
*
|
2017-08-28 |
2023-12-22 |
ユニバーシティ オブ メリーランド ボルチモア |
気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
|
|
GB201715919D0
(en)
|
2017-09-29 |
2017-11-15 |
Gw Res Ltd |
use of cannabinoids in the treatment of epilepsy
|
|
GB2588505B
(en)
|
2017-10-09 |
2022-08-03 |
Compass Pathfinder Ltd |
Preparation of psilocybin
|
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
|
US11723894B2
(en)
|
2017-10-26 |
2023-08-15 |
Terran Biosciences, Inc. |
Combination product for the treatment of neurological and/or psychiatric disorders
|
|
WO2019099402A1
(en)
|
2017-11-14 |
2019-05-23 |
Rutgers, The State University Of New Jersey |
Therapeutic compounds and methods to treat infection
|
|
JP2021514682A
(ja)
|
2018-03-08 |
2021-06-17 |
ニュー アトラス バイオテクノロジーズ エルエルシー |
トリプタミンの生産方法
|
|
CN118121577A
(zh)
|
2018-05-04 |
2024-06-04 |
感知神经科学公司 |
治疗物质滥用的方法
|
|
US10813116B2
(en)
|
2018-05-11 |
2020-10-20 |
Apple Inc. |
Support of advanced user equipment (UE) minimum processing times in new radio (NR) systems
|
|
EP3813810A4
(en)
|
2018-06-21 |
2022-03-30 |
Robert John Petcavich |
METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES
|
|
WO2020023084A1
(en)
|
2018-07-26 |
2020-01-30 |
Applied Biology, Inc. |
Taar receptor agonists for the treatment of alopecia
|
|
EP3841085B1
(en)
|
2018-08-22 |
2026-05-06 |
University Of Technology Sydney |
Nbome test
|
|
CN112912016A
(zh)
|
2018-11-07 |
2021-06-04 |
巴克斯特国际公司 |
双止回阀单手涂敷器
|
|
US11045454B2
(en)
|
2018-12-06 |
2021-06-29 |
Palo Alto Investors LP |
Methods of treating food allergy conditions
|
|
WO2020124073A1
(en)
|
2018-12-14 |
2020-06-18 |
Pear Therapeutics, Inc. |
A digital therapeutic component to optimize induction of buprenorphine-containing products
|
|
MX2021009037A
(es)
|
2019-01-30 |
2021-10-13 |
Diamond Therapeutics Inc |
Composiciones y metodos para el manejo de trastornos.
|
|
HUE066828T2
(hu)
|
2019-02-22 |
2024-09-28 |
Gh Res Ireland Limited |
5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
|
|
DK3927338T3
(da)
|
2019-02-22 |
2025-01-06 |
Gh Res Ireland Limited |
Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
|
|
WO2020176597A1
(en)
|
2019-02-27 |
2020-09-03 |
The Regents Of The University Of California |
N-substituted indoles and other heterocycles for treating brain disorders
|
|
US12616706B2
(en)
|
2019-03-07 |
2026-05-05 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
KR20220008824A
(ko)
|
2019-04-17 |
2022-01-21 |
컴퍼스 패쓰파인더 리미티드 |
실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
|
|
GB201907871D0
(en)
|
2019-06-03 |
2019-07-17 |
Small Pharma Ltd |
Therapeutic compositions
|
|
WO2021003467A1
(en)
|
2019-07-04 |
2021-01-07 |
Sw Holdings, Inc. |
Metered dosing compositions and methods of use of psychedelic compounds
|
|
FR3098407B1
(fr)
|
2019-07-10 |
2024-12-13 |
Aptar France Sas |
Dispositif de distribution nasale de poudre
|
|
US20210015738A1
(en)
|
2019-07-17 |
2021-01-21 |
Concept Matrix Solutions |
Oral dissolvable film containing psychedelic compound
|
|
GB201911024D0
(en)
|
2019-08-01 |
2019-09-18 |
Beckley Found |
Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
|
|
WO2021030571A1
(en)
|
2019-08-13 |
2021-02-18 |
University Of Maryland, Baltimore |
Methods of treating psychological and brain disorders
|
|
WO2021041407A1
(en)
|
2019-08-25 |
2021-03-04 |
Caamtech Llc |
Alkyl quarternary ammonium tryptamines and their therapeutic uses
|
|
US20230295106A1
(en)
|
2019-10-14 |
2023-09-21 |
The Regents Of The University Of California |
Ergoline-like compounds for promoting neural plasticity
|
|
HRP20220797T1
(hr)
|
2019-11-07 |
2022-10-14 |
Small Pharma Ltd |
Spojevi
|
|
US11660305B2
(en)
|
2019-11-19 |
2023-05-30 |
Turtle Bear Holdings, Llc |
Tryptamine compositions for enhancing neurite outgrowth
|
|
KR20220110759A
(ko)
|
2019-12-06 |
2022-08-09 |
나넥사 에이비 |
신규 조성물
|
|
MX2022009527A
(es)
|
2020-02-04 |
2022-11-16 |
Mindset Pharma Inc |
Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
|
|
US20210236523A1
(en)
|
2020-02-05 |
2021-08-05 |
Yale University |
Psychedelic treatment for headache disorders
|
|
LT4084791T
(lt)
|
2020-02-18 |
2025-02-25 |
Gilgamesh Pharmaceuticals, Inc. |
Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
|
|
EP3868364A1
(en)
|
2020-02-24 |
2021-08-25 |
GH Research Limited |
Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
|
|
GB202003059D0
(en)
|
2020-03-03 |
2020-04-15 |
Beckley Found |
Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
|
|
WO2021179091A1
(en)
|
2020-03-12 |
2021-09-16 |
Bright Minds Biosciences Inc. |
3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators
|
|
AU2021237640B2
(en)
|
2020-03-19 |
2024-01-04 |
Caamtech, Inc. |
Crystalline psilacetin derivatives
|
|
US11358934B2
(en)
|
2020-03-23 |
2022-06-14 |
Caamtech, Inc. |
Crystalline forms of psilacetin
|
|
US11332441B2
(en)
|
2020-03-23 |
2022-05-17 |
Caamtech, Inc. |
Crystalline N-methyl tryptamine derivatives
|
|
CA3173048A1
(en)
|
2020-04-16 |
2021-10-21 |
Fotios M. Plakogiannis |
Transdermal micro-dosing delivery of psychedelics derivatives
|
|
US20210322743A1
(en)
|
2020-04-20 |
2021-10-21 |
Indian Institute Of Technology Bombay |
Microneedle array patch for drug delivery and production method thereof
|
|
US20210322306A1
(en)
|
2020-04-21 |
2021-10-21 |
Cure Pharmaceutical Holding Corp. |
Oral dissolvable film with high load of polymeric binder
|
|
EP4142693A1
(en)
|
2020-05-01 |
2023-03-08 |
Emergex USA Corporation |
Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
|
|
WO2021226041A1
(en)
|
2020-05-04 |
2021-11-11 |
Caamtech, Inc. |
Crystalline dimethyl tryptamine analogues
|
|
AU2021267101B2
(en)
|
2020-05-05 |
2024-03-28 |
Universitätsspital Basel |
MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics
|
|
IL297861A
(en)
|
2020-05-08 |
2023-01-01 |
Psilera Inc |
Novel compositions of matter and pharmaceutical compositions
|
|
IL312785B2
(en)
|
2020-05-19 |
2026-06-01 |
Cybin Irl Ltd |
Deuterated tryptamine derivatives and methods of use
|
|
WO2021116503A2
(en)
|
2020-06-02 |
2021-06-17 |
Small Pharma Ltd |
Deuterated compounds
|
|
US12042564B2
(en)
|
2020-06-02 |
2024-07-23 |
Cybin Uk Ltd |
Therapeutic solid dosage forms
|
|
BR112022025306A2
(pt)
|
2020-06-12 |
2023-02-28 |
Beckley Psytech Ltd |
Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
|
|
GB202008961D0
(en)
|
2020-06-12 |
2020-07-29 |
Beckley Psytech Ltd |
Pharmaceutical composition
|
|
CA3173030C
(en)
|
2020-06-17 |
2024-05-14 |
Psilo Scientific Ltd. |
Predominantly phosphorylated psychoactive alkaloid extraction using alkali
|
|
CA3103707C
(en)
|
2020-12-18 |
2023-09-26 |
Ryan Moss |
Standardized psychoactive alkaloid extract composition
|
|
EP4167992A1
(en)
|
2020-06-22 |
2023-04-26 |
University of Zürich |
Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
|
|
DK4172145T3
(da)
|
2020-06-30 |
2026-07-20 |
Reunion Neuroscience Inc |
Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
|
|
WO2022008627A2
(en)
|
2020-07-07 |
2022-01-13 |
Compass Pathfinder Limited |
Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
|
|
AU2021311493A1
(en)
|
2020-07-24 |
2023-03-16 |
Mindset Pharma Inc. |
Scalable synthetic route for psilocin and psilocybin
|
|
AU2021328726A1
(en)
|
2020-08-21 |
2023-03-02 |
Compass Pathfinder Limited |
Novel psilocin derivatives having prodrug properties
|
|
US11406619B2
(en)
|
2020-08-28 |
2022-08-09 |
Small Pharma Ltd |
Injectable formulations
|
|
EP4208457A1
(en)
|
2020-09-04 |
2023-07-12 |
Gilgamesh Pharmaceuticals, Inc. |
Azetidinyl tryptamines and methods of treating psychiatric disorders
|
|
CA3192617A1
(en)
|
2020-09-20 |
2022-03-24 |
Matthew BAGGOTT |
Advantageous tryptamine compositions for mental disorders or enhancement
|
|
WO2022082058A1
(en)
|
2020-10-16 |
2022-04-21 |
Eleusis Therapeutics Us, Inc. |
Method of treatment by tryptamine alkaloids
|
|
US20230405026A1
(en)
|
2020-11-06 |
2023-12-21 |
Mynd Life Sciences Inc. |
A Method of Treating Depression by Immune Modulation
|
|
EP4247340A4
(en)
|
2020-11-18 |
2024-10-02 |
Bexson Biomedical, Inc. |
COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
|
|
WO2022104475A1
(en)
|
2020-11-19 |
2022-05-27 |
Magicmed Industries Inc. |
Nitrilated psilocybin derivatives and methods of using
|
|
EP4031529B1
(en)
|
2020-12-01 |
2023-09-27 |
Small Pharma Ltd |
Deuterated or partially deuterated n,n-dimethyltryptamine compounds
|
|
WO2022123232A1
(en)
|
2020-12-07 |
2022-06-16 |
Beckley Psytech Limited |
Pharmaceutical composition comprising psilocybin or its polymorphs
|
|
FR3117046B1
(fr)
|
2020-12-09 |
2023-02-10 |
Aptar France Sas |
Dispositif de distribution de doses de poudre
|
|
CA3201913A1
(en)
|
2020-12-09 |
2022-06-16 |
Andrew R. Chadeayne |
Dialkyl trytamines and their therapeutic uses
|
|
JP2024500397A
(ja)
|
2020-12-18 |
2024-01-09 |
コンパス パスファインダー リミテッド |
治療用途のための修飾インドールアルカロイド
|
|
EP4274831A4
(en)
|
2021-01-11 |
2024-05-01 |
Caamtech, Inc. |
Quaternary tryptamines and their therapeutic uses
|
|
EP4126857A1
(en)
|
2021-01-15 |
2023-02-08 |
Beckley Psytech Limited |
Ergoline analogues
|
|
EP4277894A1
(en)
|
2021-01-15 |
2023-11-22 |
Beckley Psytech Limited |
Tryptamine analogues
|
|
WO2022160056A1
(en)
|
2021-01-29 |
2022-08-04 |
Algernon Pharmaceuticals Inc. |
Dmt salts and their use to treat brain injury
|
|
MX2023009491A
(es)
|
2021-02-12 |
2023-10-13 |
Enveric Biosciences Canada Inc |
Derivados de psilocibina de múltiples sustituyentes y métodos de uso.
|
|
US20240189331A1
(en)
|
2021-02-12 |
2024-06-13 |
Intelgenx Corp. |
Novel tryptamine oral film formulation
|
|
FR3119772B1
(fr)
|
2021-02-15 |
2024-06-14 |
Aptar France Sas |
Tête de distribution pour dispositif de distribution nasale d’un produit fluide ou pulvérulent
|
|
US20220273628A1
(en)
|
2021-02-19 |
2022-09-01 |
Universitätsspital Basel |
Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
|
|
WO2022189662A1
(en)
|
2021-03-12 |
2022-09-15 |
Alvarius Pharmaceuticals Ltd. |
Compositions and methods for treating addictions comprising 5-meo-dmt
|
|
CA3212065A1
(en)
|
2021-03-15 |
2022-09-22 |
James Gilligan |
Improved methods for the use of psychedelics
|
|
AU2022239825C1
(en)
|
2021-03-18 |
2026-08-13 |
Cybin Irl Limited |
Psilocybin analogs, salts, compositions, and methods of use
|
|
CN117177959A
(zh)
|
2021-03-18 |
2023-12-05 |
赛本爱尔兰有限公司 |
裸头草碱类似物、盐、组合物和使用方法
|
|
FR3121047B1
(fr)
|
2021-03-29 |
2023-07-14 |
Aptar France Sas |
Dispositif de distribution nasale de poudre
|
|
MX2023011326A
(es)
|
2021-03-30 |
2023-10-03 |
Compass Pathfinder Ltd |
Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
|
|
CA3216889A1
(en)
|
2021-04-26 |
2022-11-03 |
Glenn Short |
Novel n,n-dimethyltryptamine compositions and methods
|
|
US20230136824A1
(en)
|
2021-04-26 |
2023-05-04 |
ATAI Life Sciences AG |
N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
|
|
US20220362237A1
(en)
|
2021-05-03 |
2022-11-17 |
Mind Medicine, Inc. |
Psychedelics for treatment of pain
|
|
EP4333979A4
(en)
|
2021-05-03 |
2025-01-15 |
Mind Medicine, Inc. |
Method of titrating dose of psychedelics
|
|
WO2022235514A1
(en)
|
2021-05-04 |
2022-11-10 |
Mind Medicine, Inc. |
Liposome delivery of psychedelics
|
|
EP4792879A2
(en)
|
2021-05-17 |
2026-08-19 |
Cybin IRL Limited |
Formulations of psilocybin
|
|
CN113288883A
(zh)
|
2021-05-24 |
2021-08-24 |
河南科技大学 |
一种长效缓解抑郁微针贴片及其制备方法
|
|
KR20240013170A
(ko)
|
2021-05-25 |
2024-01-30 |
아타이 테라퓨틱스, 인크. |
신규 n,n-디메틸트립타민 염 및 결정질 염 형태
|
|
WO2022246572A1
(en)
|
2021-05-26 |
2022-12-01 |
Mindset Pharma Inc. |
Hallucinogen-fatty acid combination
|
|
IL309210A
(en)
|
2021-06-09 |
2024-02-01 |
Atai Therapeutics Inc |
Parent drugs and conjugates of dimethyltryptamine
|
|
US20230024991A1
(en)
|
2021-06-23 |
2023-01-26 |
ATAI Life Sciences AG |
Prodrugs of acyl carnitines
|
|
WO2023283386A2
(en)
|
2021-07-07 |
2023-01-12 |
Arcadia Medicine, Inc. |
Safer psychoactive compositions
|
|
IL310296A
(en)
|
2021-07-22 |
2024-03-01 |
Gh Res Ireland Limited |
A method for the preparation of a tryptamine derivative
|
|
EP4137131A1
(en)
|
2021-08-17 |
2023-02-22 |
Centre National de la Recherche Scientifique (CNRS) |
Novel serotonin analogues and their uses for treating iron-associated disorders
|
|
WO2023028086A1
(en)
|
2021-08-23 |
2023-03-02 |
Gilgamesh Pharmaceuticals, Inc. |
Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists
|
|
AU2022342266B2
(en)
|
2021-09-08 |
2026-03-26 |
Cybin Irl Limited |
Combination drug therapies
|
|
EP4159201A1
(en)
|
2021-09-30 |
2023-04-05 |
Biomind Labs Inc |
Encapsulated microparticles and nanoparticles of dimethyltriptamines
|
|
EP4408412A4
(en)
|
2021-09-30 |
2025-07-16 |
ATAI Life Sciences AG |
COMPOSITIONS AND METHODS FOR TREATING HEADACHES
|
|
US20230310374A1
(en)
|
2021-09-30 |
2023-10-05 |
ATAI Life Sciences AG |
Compositions and methods for treating headache or facial pain
|
|
EP4159192A1
(en)
|
2021-09-30 |
2023-04-05 |
Biomind Labs Inc |
Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
|
|
WO2023076135A1
(en)
|
2021-10-29 |
2023-05-04 |
Psilera Inc. |
N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
|
|
EP4423062A4
(en)
|
2021-10-29 |
2025-08-27 |
Psilera Inc |
MODIFIED INDOLE COMPOUNDS
|
|
AU2022413759A1
(en)
|
2021-12-13 |
2024-06-27 |
Beckley Psytech Limited |
Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
|
|
US20260041667A1
(en)
|
2021-12-13 |
2026-02-12 |
Beckley Psytech Limited |
Prescription digital therapeutics
|
|
US20260035334A1
(en)
|
2021-12-13 |
2026-02-05 |
Beckley Psytech Limited |
Method of synthesis
|
|
US20250064782A1
(en)
|
2021-12-17 |
2025-02-27 |
Journey Colab Corp. |
Methods of Treating Substance Use Disorders Using 5-MeO-DMT
|
|
CA3244229A1
(en)
|
2021-12-24 |
2023-06-29 |
Psylo Pty Ltd |
COMPOUNDS
|
|
JP2025501141A
(ja)
|
2021-12-24 |
2025-01-17 |
サイロ プロプリエタリー リミテッド |
化合物
|
|
US11912680B2
(en)
|
2021-12-28 |
2024-02-27 |
Empathbio, Inc. |
Nitric oxide releasing prodrugs of MDA and MDMA
|
|
CA3238440A1
(en)
|
2021-12-30 |
2023-07-06 |
Atai Therapeutics, Inc. |
Dimethyltryptamine analogues as nitric oxide delivery drugs
|
|
KR20250005182A
(ko)
|
2022-03-27 |
2025-01-09 |
지에이치 리서치 아일랜드 리미티드 |
인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민
|
|
WO2023186834A1
(en)
|
2022-03-27 |
2023-10-05 |
GH Research Ireland Limited |
Crystalline hydrobromide salt of 5-meo-dmt
|
|
JP2025510368A
(ja)
|
2022-03-27 |
2025-04-14 |
ジーエイチ・リサーチ・アイルランド・リミテッド |
不安の処置
|
|
WO2024010537A1
(en)
|
2022-07-07 |
2024-01-11 |
Cemaks Endüstri̇yel Maki̇ne Sanayi̇ Anoni̇m Şi̇rketi̇ |
Packaging machine for packaging polymer based products
|
|
AU2023311967A1
(en)
|
2022-07-19 |
2025-02-06 |
Pinata Holdings Inc. |
Inhalable serotonin receptor agonist formulations
|
|
US12264131B2
(en)
|
2022-08-19 |
2025-04-01 |
Beckley Psytech Limited |
Pharmaceutically acceptable salts and compositions thereof
|
|
GB202212116D0
(en)
|
2022-08-19 |
2022-10-05 |
Beckley Psytech Ltd |
Pharmaceutically acceptable salts and Compositions thereof
|
|
EP4584247A2
(en)
|
2022-09-06 |
2025-07-16 |
ATAI Therapeutics, Inc. |
Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors
|
|
EP4608395A2
(en)
|
2022-10-26 |
2025-09-03 |
ATAI Therapeutics, Inc. |
N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
|
|
WO2024105379A1
(en)
|
2022-11-14 |
2024-05-23 |
Beckley Psytech Limited |
Formulations of 5-meo-dmt
|
|
WO2024108195A1
(en)
|
2022-11-17 |
2024-05-23 |
Remedi, Inc. |
Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
|
|
WO2024118767A2
(en)
|
2022-11-29 |
2024-06-06 |
Caamtech, Inc. |
Tryptamine derivatives
|
|
TW202430149A
(zh)
|
2022-12-01 |
2024-08-01 |
美商雅特益醫療公司 |
N,n-二甲基色胺之結晶形式及其使用方法
|
|
EP4633625A2
(en)
|
2022-12-15 |
2025-10-22 |
ATAI Therapeutics, Inc. |
Prodrugs of dimethyltryptamine and derivatives thereof
|
|
JP2026501759A
(ja)
|
2023-01-04 |
2026-01-16 |
ジーエイチ・リサーチ・アイルランド・リミテッド |
薬物パッド
|
|
CN120813348A
(zh)
|
2023-01-30 |
2025-10-17 |
Gh研究爱尔兰有限公司 |
用于治疗产后抑郁的5-甲氧基-n,n-二甲基色胺
|
|
JP2026505778A
(ja)
|
2023-01-30 |
2026-02-18 |
ジーエイチ・リサーチ・アイルランド・リミテッド |
産後うつ病の処置における5-meo-dmtの使用
|
|
IL322810A
(en)
|
2023-02-17 |
2025-10-01 |
Native Code Bio Llc |
Therapeutic combinations for inflammatory conditions and diseases
|
|
EP4704833A2
(en)
|
2023-04-27 |
2026-03-11 |
ATAI Therapeutics, Inc. |
Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines
|
|
GB202306256D0
(en)
|
2023-04-27 |
2023-06-14 |
Beckley Psytech Ltd |
5-Methoxy-N,N-Dimethyltryptamine Formulations
|
|
JP2026518190A
(ja)
|
2023-05-24 |
2026-06-04 |
サイレラ インコーポレイテッド |
トリプタミン誘導体を含む製剤およびそれらの使用
|
|
GB202308830D0
(en)
|
2023-06-13 |
2023-07-26 |
Beckley Psytech Ltd |
5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
|
|
US20250193970A1
(en)
|
2023-06-13 |
2025-06-12 |
Beckley Psytech Limited |
5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONS
|
|
US12246005B2
(en)
|
2023-06-13 |
2025-03-11 |
Beckley Psytech Limited |
5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
|
|
WO2024256821A1
(en)
|
2023-06-13 |
2024-12-19 |
Beckley Psytech Limited |
Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
|
|
EP4746873A1
(en)
|
2023-07-19 |
2026-05-27 |
ATAI Therapeutics, Inc. |
Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same
|
|
EP4750467A1
(en)
|
2023-07-25 |
2026-06-03 |
ATAI Therapeutics, Inc. |
Compositions for limiting sympathomimetic effects of psychedelic therapeutics
|
|
EP4773958A1
(en)
|
2023-09-08 |
2026-07-15 |
ATAI Therapeutics, Inc. |
Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
|
|
EP4784121A1
(en)
|
2023-09-28 |
2026-08-05 |
Beckley Psytech Limited |
Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
|
|
EP4788322A1
(en)
|
2023-10-02 |
2026-08-12 |
ATAI Therapeutics, Inc. |
N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof
|
|
TW202547567A
(zh)
|
2023-10-18 |
2025-12-16 |
愛爾蘭商Gh研究愛爾蘭有限公司 |
用於氣溶膠化藥物給藥之設備、系統及方法
|
|
WO2025137581A1
(en)
|
2023-12-21 |
2025-06-26 |
Atai Therapeutics, Inc. |
Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions
|
|
WO2025170990A1
(en)
|
2024-02-06 |
2025-08-14 |
Atai Therapeutics, Inc. |
Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor
|
|
WO2026030301A1
(en)
|
2024-07-29 |
2026-02-05 |
Atai Therapeutics, Inc. |
Methods of treating treatment resistant depression
|